Clinical trial
JP-1730 to Treat Parkinson's Disease
NCT00040209 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00040209 |
|---|---|
| Title | JP-1730 to Treat Parkinson's Disease |
| Official title | Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | JP 1730, IV Levodopa, IV Apomorphine |
| Enrollment | 30 |
| Start date | Jun 1, 2002 |
| Completion | Jul 1, 2005 |
| First posted | Jun 24, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: